Literature DB >> 15584905

S100B protein is released by in vitro trauma and reduces delayed neuronal injury.

Karen A Willoughby1, Andrea Kleindienst, Christian Müller, Tao Chen, Judith K Muir, Earl F Ellis.   

Abstract

S100B protein in brain is produced primarily by astrocytes, has been used as a marker for brain injury and has also been shown to be neurotrophic and neuroprotective. Using a well characterized in vitro model of brain cell trauma, we examined the potential role of exogenous S100B in preventing delayed neuronal injury. Neuronal plus glial cultures were grown on a deformable Silastic membrane and then subjected to strain (stretch) injury produced by a 50 ms displacement of the membrane. We have previously shown that this injury causes an immediate, but transient, nuclear uptake of the fluorescent dye propidium iodide by astrocytes and a 24-48 h delayed uptake by neurons. Strain injury caused immediate release of S100-beta with further release by 24 and 48 h. Adding 10 or 100 nm S100B to injured cultures at 15 s, 6 h or 24 h after injury reduced delayed neuronal injury measured at 48 h. Exogenous S100B was present in the cultures through 48 h. These studies directly demonstrate the release and neuroprotective role of S100B after traumatic injury and that, unlike most receptor antagonists used for the treatment of trauma, S100B is neuroprotective when given at later, more therapeutically relevant time points.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15584905     DOI: 10.1111/j.1471-4159.2004.02812.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  21 in total

Review 1.  Predictive biomarkers of recovery in traumatic brain injury.

Authors:  Sabrina Giacoppo; Placido Bramanti; Marina Barresi; Debora Celi; Valeria Foti Cuzzola; Eleonora Palella; Silvia Marino
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

Review 2.  Multifarious diagnostic possibilities of the S100 protein family: predominantly in pediatrics and neonatology.

Authors:  Anna Medkova; Josef Srovnal; Jarmila Potomkova; Jana Volejnikova; Vladimir Mihal
Journal:  World J Pediatr       Date:  2018-06-01       Impact factor: 2.764

3.  TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.

Authors:  M M Edwards; S R Robinson
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

Review 4.  A systematic review of the biomarker S100B: implications for sport-related concussion management.

Authors:  Stefanie Schulte; Leslie W Podlog; J Jordan Hamson-Utley; Frederick G Strathmann; Heiko K Strüder
Journal:  J Athl Train       Date:  2014 Nov-Dec       Impact factor: 2.860

5.  S100B protein in tissue development, repair and regeneration.

Authors:  Guglielmo Sorci; Francesca Riuzzi; Cataldo Arcuri; Claudia Tubaro; Roberta Bianchi; Ileana Giambanco; Rosario Donato
Journal:  World J Biol Chem       Date:  2013-02-26

6.  The Passage of S100B from Brain to Blood Is Not Specifically Related to the Blood-Brain Barrier Integrity.

Authors:  Andrea Kleindienst; Christian Schmidt; Hans Parsch; Irene Emtmann; Yu Xu; Michael Buchfelder
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-07-08

7.  S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond.

Authors:  Guglielmo Sorci; Roberta Bianchi; Francesca Riuzzi; Claudia Tubaro; Cataldo Arcuri; Ileana Giambanco; Rosario Donato
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-08-18

8.  Serum S100B but not NSE levels are increased in morbidly obese individuals affected by obstructive sleep apnea-hypopnea syndrome.

Authors:  Leandro Giacometti da Silva; Cláudio Corá Mottin; Diogo Onofre Souza; Luiz Valmor Portela; Carla Winei Braga; Carolina Boeira Vargas; Alexandre Vontobel Padoin; Denis Martinez; Renato Dutra Dias
Journal:  Obes Surg       Date:  2008-04-18       Impact factor: 4.129

Review 9.  Functions of S100 proteins.

Authors:  R Donato; B R Cannon; G Sorci; F Riuzzi; K Hsu; D J Weber; C L Geczy
Journal:  Curr Mol Med       Date:  2013-01       Impact factor: 2.222

Review 10.  Therapeutic potential of fluoxetine in neurological disorders.

Authors:  Jop P Mostert; Marcus W Koch; Marco Heerings; Dorothea J Heersema; Jacques De Keyser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.